newsfilter
← Latest News
GlobeNewswire·

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results

FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology On track to